Medtronic Seeks InFuse Add-on, Proposes Clearer Definition Of “Similarity”
This article was originally published in The Gray Sheet
Executive Summary
CMS should reconsider granting new technology add-on payment for Medtronic's InFuse bone graft for tibia fractures by using a clearer definition of "substantial improvement," according to the company
You may also be interested in...
Medtronic Bone Graft Reimbursement Fate Fused With Stryker’s In CMS Rule
CMS' proposed decision to deny a new-technology add-on to Medtronic's InFuse bone graft reaffirms that "substantial clinical improvement" ranks last in the hierarchy of evidence required for the payment
Medtronic Bone Graft Reimbursement Fate Fused With Stryker’s In CMS Rule
CMS' proposed decision to deny a new-technology add-on to Medtronic's InFuse bone graft reaffirms that "substantial clinical improvement" ranks last in the hierarchy of evidence required for the payment
Gore Seeks Add-On Payment For TAG Endograft In Advance Of FDA Approval
W. L. Gore is requesting new technology add-on payment from Medicare for its TAG thoracic aortic aneurysm (TAA) endograft based on data showing it to be significantly safer than surgical repair